Advancing Treatment for NRG1 Fusion+ Lung and Pancreatic Cancers - Episode 1

Prevalence of NRG1 Fusions in Lung Cancer

D. Ross Camidge, MD, PhD, of University of Colorado Health Lung Cancer Clinic – Anschutz Medical Campus, discusses the prevalence of NRG1 fusions in lung cancer.

Now Viewing
EP. 1: Prevalence of NRG1 Fusions in Lung Cancer
EP. 2: Differences Between DNA and RNA Testing for NRG1
EP. 3: Standard Treatments for NRG1 Fusion+ NSCLC
EP. 4: Ongoing Research Efforts Targeting NRG1 in Lung Cancer
EP. 5: Efficacy With NRG1-Directed Agents in NSCLC
EP. 6: Prognosis, Rarity of NRG1+ Pancreatic Cancer
EP. 7: Choosing RNA Over DNA Testing for NRG1 Fusions in Pancreatic Cancer
EP. 8: Standard Treatment Regimens for NRG1+ Pancreatic Cancer
EP. 9: Poised Potential With Zenocutuzumab in NRG1+ Pancreatic Cancer
EP. 10: Current Approaches and Treatment Challenges in NRG1+ NSCLC and Pancreatic Cancer
EP. 11: DNA vs RNA Sequencing in NSCLC and Pancreatic Cancer
EP. 12: A Physician Assistant's Perspective: Treatment Planning in NRG1+ NSCLC and Pancreatic Cancer
EP. 13: The Potential Role for Zenocutuzumab in NRG1+ NSCLC and Pancreatic Cancer
EP. 14: Using a Multidisciplinary Treatment Approach in NRG1+ NSCLC and Pancreatic Cancer

Related Content:

Lung CancerPrecision Medicine in Oncology®
Adding an HPK1 Inhibitor to Immune Checkpoint Inhibition May Be Effective in Solid Tumors
Osimertinib Approaches EU Approval in Locally Advanced EGFR+ NSCLC After Chemoradiation
Dr Pobel on the Prognostic Value of Phenotypic and Genomic Characterization in De Novo mCSPC